Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.65
SUPN's Cash to Debt is ranked higher than
72% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. SUPN: 1.65 )
SUPN' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 1.65

Equity to Asset 0.35
SUPN's Equity to Asset is ranked higher than
51% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SUPN: 0.35 )
SUPN' s 10-Year Equity to Asset Range
Min: -2.25   Max: 0.61
Current: 0.35

-2.25
0.61
F-Score: 4
Z-Score: 0.71
M-Score: 24.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -75.87
SUPN's Operating margin (%) is ranked higher than
51% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. SUPN: -75.87 )
SUPN' s 10-Year Operating margin (%) Range
Min: -37851.89   Max: 27.1
Current: -75.87

-37851.89
27.1
Net-margin (%) -116.87
SUPN's Net-margin (%) is ranked lower than
51% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. SUPN: -116.87 )
SUPN' s 10-Year Net-margin (%) Range
Min: -36285.85   Max: 6701.74
Current: -116.87

-36285.85
6701.74
ROE (%) -204.05
SUPN's ROE (%) is ranked lower than
54% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. SUPN: -204.05 )
SUPN' s 10-Year ROE (%) Range
Min: -202.72   Max: -138.13
Current: -204.05

-202.72
-138.13
ROA (%) -52.68
SUPN's ROA (%) is ranked lower than
52% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. SUPN: -52.68 )
SUPN' s 10-Year ROA (%) Range
Min: -90.03   Max: 106.84
Current: -52.68

-90.03
106.84
ROC (Joel Greenblatt) (%) -1058.53
SUPN's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. SUPN: -1058.53 )
SUPN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3115.47   Max: 1356
Current: -1058.53

-3115.47
1356
Revenue Growth (%) 75.70
SUPN's Revenue Growth (%) is ranked higher than
98% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SUPN: 75.70 )
SUPN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 75.7
Current: 75.7

0
75.7
EBITDA Growth (%) -52.20
SUPN's EBITDA Growth (%) is ranked lower than
52% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SUPN: -52.20 )
SUPN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -52.2
Current: -52.2

EPS Growth (%) -52.30
SUPN's EPS Growth (%) is ranked higher than
52% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. SUPN: -52.30 )
SUPN' s 10-Year EPS Growth (%) Range
Min: 0   Max: -52.3
Current: -52.3

» SUPN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SUPN Guru Trades in

SUPN Guru Trades in

SUPN Guru Trades in

Q2 2014

SUPN Guru Trades in Q2 2014

Robert Bruce 100,000 sh (New)
Louis Moore Bacon 100,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Bruce 2014-06-30 New Buy0.25%$7.32 - $10.85 $ 7.8-12%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.86
SUPN's P/B is ranked higher than
52% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. SUPN: 9.86 )
SUPN' s 10-Year P/B Range
Min: 2.61   Max: 18.63
Current: 9.86

2.61
18.63
P/S 5.76
SUPN's P/S is ranked higher than
63% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SUPN: 5.76 )
SUPN' s 10-Year P/S Range
Min: 6.18   Max: 139.8
Current: 5.76

6.18
139.8
EV-to-EBIT -8.37
SUPN's EV-to-EBIT is ranked higher than
58% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. SUPN: -8.37 )
SUPN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -8.37

Current Ratio 3.75
SUPN's Current Ratio is ranked higher than
83% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SUPN: 3.75 )
SUPN' s 10-Year Current Ratio Range
Min: 1.51   Max: 7.26
Current: 3.75

1.51
7.26
Quick Ratio 3.23
SUPN's Quick Ratio is ranked higher than
84% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. SUPN: 3.23 )
SUPN' s 10-Year Quick Ratio Range
Min: 1.51   Max: 7.26
Current: 3.23

1.51
7.26

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.82
SUPN's Price/Tangible Book is ranked higher than
59% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. SUPN: 10.82 )
SUPN' s 10-Year Price/Tangible Book Range
Min: 3.85   Max: 19.29
Current: 10.82

3.85
19.29
Price/Median PS Value 0.15
SUPN's Price/Median PS Value is ranked higher than
100% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. SUPN: 0.15 )
SUPN' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 3.12
Current: 0.15

0.21
3.12

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S49.Germany
Supernus Pharmaceuticals Inc., was incorporated in 2005. It was incorporated in the state of Delaware. It is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. It is a developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and attention deficit hyperactivity disorder, or ADHD. The company intends to market its product candidates in the United States through its own focused sales force targeting specialty physicians, including neurologists and psychiatrists. The company's current pipeline of novel product candidates includes: SPN-538: SPN-538, is a novel oral once-daily extended release topiramate product for the treatment of epilepsy; Epliga: Epliga is a novel oral once-daily extended release formulation of oxcarbazepine and is currently in Phase III trials; SPN-810: SPN-810 which is currently in Phase II, as a novel treatment for impulsive aggression in patients with ADHD. If approved by the FDA, SPN-810 could be the first product available to address this serious, unmet medical need; SPN-812: SPN-812 which is currently in Phase II, as a novel non-stimulant treatment for ADHD. SPN-812 is a selective norepinephrine reuptake inhibitor that could be more effective and have a better side effect profile than other non-stimulant treatments for ADHD. The company's goal is to be a specialty pharmaceutical company developing and commercializing new medicines in neurology and psychiatry. Build in-house sales and marketing capabilities, focused on specialty markets in the United States, to promote SPN-538 and Epliga. The company is currently focused on attaining regulatory approval for, and bringing two late-stage epilepsy product candidates, SPN-538 and Epliga, to market. It is the owner of various U.S. federal trademark registrations () and registration applications (TM), including the following marks referred to in this prospectus pursuant to applicable U.S. intellectual property laws: "Supernus," "Epliga," "Microtrol," "Solutrol," "ProScreen," "OptiScreen," "ProPhile," and the registered Supernus Pharmaceuticals logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. The company's revenues have been generated through research and development agreements. These agreements included fees for development services provided to customers and payments for achievement of specified development, regulatory and sales milestones, which comprise development and milestone revenues, as well as royalties on product sales of licensed products, Oracea, Sanctura XR, and Intuniv, which comprise its royalty revenues. It recognizes development and milestone revenues related to research and development agreements pursuant to which various third parties have accessed its proprietary technologies. Government authorities in the United States at t
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 


More From Other Websites
Supernus' Trokendi XR Faces Generic Threat from Zydus Oct 15 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 15 2014
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Oct 14 2014
Supernus Up, Files Lawsuit against Actavis for Trokendi XR Oct 06 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 03 2014
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents Oct 02 2014
Dr. Reddy's (RDY) Generic Xopenex Launched in the US Sep 25 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 24 2014
Supernus Confirms 2014 Outlook, Epilepsy Products in Focus Sep 23 2014
Supernus Provides Business Update Sep 22 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Sep 18 2014
Others Overlooked Supernus Pharmaceuticals (SUPN), Should You Buy It Now? Sep 10 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 08 2014
Supernus Announces Issuance of Fourth US Patent Protecting Oxtellar XR(R) Sep 04 2014
Why You Shouldn't Bet Against Supernus Pharmaceuticals (SUPN) Stock Sep 04 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 25 2014
Supernus' Trokendi XR Faces Generic Threat from Actavis Aug 22 2014
The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, Gilead Sciences,... Aug 21 2014
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Aug 21 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK